WEIRD Testbeds with Fixed and Mobile WiMAX Technology for User Applications, Telemedicine and Monitoring of Impervious Areas

Wireless Metropolitan Area Networks based on IEEE 802.16d/e standards are soon to be deployed in several countries. However, there is lack of published literature with results from actual test¬beds. This paper introduces the work done in the EU Sixth Framework Programme Project WEIRD to design and set up WiMAX testbeds in four EU countries. We describe the method¬ology followed, detail our implementation and present results from the testbeds, as deployed in the first phase of WEIRD. The testbeds are used to demonstrate how WiMAX technology can be used to extend the connectivity of the pan-European data com¬munications network (GEANT2) to isolated and impervious ar¬eas and, furthermore, to assure end-to-end quality of service to novel applications.SIGARCH, Create-NetPublishedInnsbruck, Austria1.4. TTC - Sorveglianza sismologica delle aree vulcaniche attiveope

WEIRD Testbeds with Fixed and Mobile WiMAX Technology for User Applications, Telemedicine and Monitoring of Impervious Areas

Wireless Metropolitan Area Networks based on IEEE 802.16d/e standards are soon to be deployed in several countries. However, there is lack of published literature with results from actual test¬beds. This paper introduces the work done in the EU Sixth Framework Programme Project WEIRD to design and set up WiMAX testbeds in four EU countries. We describe the method¬ology followed, detail our implementation and present results from the testbeds, as deployed in the first phase of WEIRD. The testbeds are used to demonstrate how WiMAX technology can be used to extend the connectivity of the pan-European data com¬munications network (GEANT2) to isolated and impervious ar¬eas and, furthermore, to assure end-to-end quality of service to novel applications

The Bravehealth Software Architecture for the Monitoring of Patients Affected by CVD

The Bravehealth project is a large scale Integrated Project (IP) launched in the 7th Framework Programme. Bravehealth proposes a patient-centric vision to Cardio Vascular Disease (CVD) management and treatment, providing people already diagnosed as subjects at risk with a sound solution for continuous and remote monitoring and real time prevention of malignant events. Mainly, this paper describes the BVH Software Architecture. The role and the rationale behind the various system components is widely explained. The set of adopted technological solutions is presented and, finally, it is shown how the architecture succeeds in achieving a flexible, scalable and efficient system able to cope with many different medical scenarios

The SHIELD approach

With a business baseline focused on the impact of embedded systems in the years ahead, the book investigates the Security, Privacy and Dependability (SPD) requirements raised from existing and future IoT, Cyber-Physical and M2M systems. It proposes a new approach to embedded systems SPD, the SHIELD philosophy, that relies on an overlay approach to SPD, on a methodology for composable SPD, on the use of semantics, and on the design of embedded systems with built-in SPD. The book explores new ground and illustrates the development of approximately forty prototypes capable of managing and enhancing SPD, including secure boot, trusted execution environments, adaptable radio interfaces, and different implementations of the middleware for measuring and composing SPD

MMP Inhibition in Prostate Cancer

Matrix metalloproteinases (MMPs) play a significant role during the development and metastasis of prostate cancer (CaP). CaP cells secrete high levels of MMPs and low levels of endogenous MMP inhibitors (TIMPs), thus creating an excess balance of MMPs. Established CaP cell lines that express high levels of MMPs frequently metastasize to the bone and the lungs. Drugs such as Taxol and alendronate that reduce cell motility and calcium metabolism reduce bony metastasis of xenografted CaP tumors. We tested several synthetic, nontoxic inhibitors of MMPs that can be administered orally, including doxycycline (DC) and chemically modified tetracyclines (CMTs) on CaP cells in vitro and on a rat CaP model in vivo. Among several anti‐MMP agents tested, CMT‐3 (6‐deoxy, 6‐demethyl,4‐de‐dimethylamino tetracycline) showed highest activity against CaP cell invasion and cell proliferation. Micromolar concentration of CMT‐3 and DC inhibited both the secretion and activity of MMPs by CaP cells. When tested for in vivo efficacy in the Dunning rat CaP model by daily oral gavage, CMT‐3 and DC both reduced the lung metastases (> 50%). CMT‐3, but not DC, inhibited tumor incidence (55 ± 9%) and also reduced the tumor growth rate (27 ± 9.3%). More significantly, the drugs showed minimum systemic toxicity. Ongoing studies indicate that CMT‐3 may inhibit the skeletal metastases of CaP cells and delay the onset of paraplegia due to lumbar metastases. These preclinical studies provide the basis for clinical trials of CMT‐3 for the treatment of metastatic disease